Accelovance snags another Big Pharma cancer vet to boost its onco profile

CRO Accelovance has appointed an oncologist with deep roots in drug development to help steer its efforts in cancer R&D, replacing the company's last big get in the field.

Mark Gelder is joining the company as vice president of medical affairs for oncology, leaving his post as head of clinical development at Inovio Pharmaceuticals ($INO). Before joining that company this year, Gelder held oncology leadership positions at Wyeth, Bayer, GE Healthcare ($GE) and Pfizer ($PFE), a tour that exposed him to every phase of the development process, from early research to regulatory approval, Accelovance said.

Gelder replaces Joseph Purvis, an oncology veteran with experience at Otsuka and Pfizer who joined Accelovance in October. Purvis decamped for Quintiles ($Q) earlier this year.

Meanwhile, Accelovance is in the midst of an expansion, planning to open a new research hub in Wales and add 70 jobs in the process. The move comes on the heels of Accelovance's February acquisition of the U.K.'s Altair Clinical, since renamed Accelovance Europe. That deal brought the CRO new outposts in England and Russia, plus staff throughout Europe, the Middle East and North Africa.

- read the statement

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.